-
A Retrospective Analysis of Tissue, Liquid, and Germline Testing in Hispanic and Non-Hispanic Men with Advanced Hormone-Sensitive Prostate Cancer - Beyond the Abstract
22 Apr 2025 23:57 GMT
… and pathological differences in prostate cancer (PCa) between Hispanic … chromosomal aberrations in prostate cancer (PCa), and … advanced hormone-sensitive prostate cancer (PCa). Considering … Department of Medicine, Mayo Clinic, Scottsdale, AZ.
University …
-
Current and future directions in theranostics for neuroendocrine prostate cancer.
22 Apr 2025 16:05 GMT
Neuroendocrine prostate cancer (NEPC) is rare at the … Radiation Oncology, Mayo Clinic Rochester, MN, USA., Department of Oncology, Mayo Clinic Rochester, MN … and Pathology, Mayo Clinic Rochester, MN, USA., Department of Radiology, Mayo Clinic Rochester, MN …
-
Hidden in plain sight: Prostate cancer survivor praises Mizzou's breakthrough treatment
15 Apr 2025 17:03 GMT
… that are being treated at Mayo Clinic, at MD Anderson, as well … Ohnesorge, who was diagnosed with prostate cancer in 2020.
"I thought …
-
BriaCell Presents Benchmark Beating Survival and Clinical Benefit at AACR 2025; Advancements in Next Generation Bria-OTS+™ Development
28 Apr 2025 11:30 GMT
… and Professor of Oncology, Mayo Clinic. “Treatment options have been … cancer and Bria-PROS+ prostate cancer programs,” stated Dr. William … Bria-PROS+™ for prostate cancer are expected to be … cancer and Bria-PROS+ prostate cancer programs; and expectations for …
-
Ascentage Pharma Presents Results from Five Preclinical Studies at 2025 American Association of Cancer Research (AACR) Annual Meeting, Highlighting Strong Synergistic Effects of Olverembatinib Combined with Lisaftoclax
28 Apr 2025 11:00 GMT
… inhibitor enzalutamide in preclinical prostate cancer (PCa) models
Abstract … Introduction: Castration-resistant prostate cancer (CRPC) remains incurable … of patients with prostate cancer, which is … Farber Cancer Institute, Mayo Clinic, National Cancer …
-
FDA Approves Novartis' Pluvicto for Prostate Cancer Patients
31 Mar 2025 21:08 GMT
… Director of Radiopharmaceutical Clinical Trials, Mayo Clinic. "The trial data … Treatment for Castrate-Resistant Metastatic Prostate Cancer After First-Line Androgen … overall survival in castration-resistant prostate cancer: results from SEARCH. Clin …
-
FDA Approves Expanded Label of Novartis’ Prostate Cancer Treatment, Pluvicto
28 Mar 2025 22:04 GMT
… PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been … of radiophar-maceutical clinical trials, Mayo Clinic added: "The clinical … psma-positive-metastatic-castration-resistant-prostate-cancer-302414516.html
2. Novartis …
-
FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer
28 Mar 2025 17:48 GMT
… Clinical Trials, Mayo Clinic. "The … sensitive prostate cancer (PSMAddition, NCT04720157) and oligometastatic prostate cancer ( … metastatic castration-resistant prostate cancer (PSMA-positive … -castration-resistant-prostate-cancer-302414516.html …
-
Health Check: Telix licks its wounds after FDA knocks back brain cancer diagnostic
28 Apr 2025 03:17 GMT
… FDA has approved two Telix prostate cancer diagnostics. The company is deriving … portable stroke detection tool, at Mayo Clinic in Jacksonville, Florida.
The company …
-
Retrospective Comparative Analysis of Prostate Cancer In-Basket Messages: Responses From Closed-Domain Large Language Models Versus Clinical Teams.
27 Mar 2025 07:21 GMT
… message response generation for prostate cancer treatment, with the goal … patients with nonmetastatic prostate cancer from the Mayo Clinic Department of Radiation … oncology generative pretrained transformer.
Mayo Clinic proceedings. Digital health. 2025 …
About
© 1995-2025